Carson C. Block · research-note
Chinook Therapeutics Inc (KDNY)
36 pages · 3 arc beats · 2 loops
Chinook Therapeutics Inc (KDNY)
Carson C. Block · 2023-05 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
124681012141618202224262830323436
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 20 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
The Monster 4 slides 100% 4/4 slides 100% 4/4 slides · 27 hits — 0/4 slides
— 0/4 slides
25% 1/4 slides 100% 4/4 slides — 0/4 slides
The Struggle 10 slides 100% 10/10 slides 100% 10/10 slides · 71 hits — 0/10 slides
— 0/10 slides
40% 4/10 slides 100% 10/10 slides 100% 10/10 slides The Victory 6 slides 100% 6/6 slides 100% 6/6 slides · 45 hits — 0/6 slides
— 0/6 slides
50% 3/6 slides 100% 6/6 slides 100% 6/6 slides Slide inventory
36 every slide · same image gating as the playbook
02
This is a research note page from a short-seller report.diagnose_problem
Open slide detailBeat · The Monster
03
This slide serves as a critical analysis of clinical trial integrity, specifically focusing on the SONAR trial and subsequent reporting practices.expose_contradiction
Open slide detailBeat · The Monster
04
This slide serves as a critique of clinical trial design and reporting practices, specifically regarding the SONAR trial.diagnose_problem
Open slide detailBeat · The Monster
05
The text highlights discrepancies in reported ESKD numbers between different sources and questions the statistical significance of the primary renal outcome.analyze_data
Open slide detailBeat · The Monster
06
The slide uses data from the RADAR trial to challenge the validity of UACR as a reliable surrogate endpoint for kidney function.expose_contradiction
07
The text argues that the rapid reversal of UACR effects upon drug cessation indicates a transient hemodynamic impact rather than structural renal improvement.expose_contradiction
08
The slide argues that the drug Atrasentan acts as a 'band-aid' by masking symptoms via surrogate endpoints without providing long-term structural benefit.analyze_data
09
The slide uses Kaplan-Meier survival curves to illustrate the convergence of outcomes between placebo and Atrasentan groups.expose_contradiction
10
The slide provides a critical analysis of a standard medical metric, highlighting its inaccuracies and limitations in clinical practice.analyze_data
11
The slide functions as a critique of clinical trial data integrity, specifically focusing on the inclusion of serum creatinine doubling and the use of inulin asexpose_contradiction
12
The slide uses bar charts to show baseline vs treatment effects on GFR, ERBF, EFF, and ERVR, suggesting these metrics are influenced by blood dilution.expose_contradiction
13
The slide uses a table to highlight discrepancies in mortality reporting between the 'Enrichment' group and the 'Double-Blind' groups.expose_contradiction
14
Includes references to clinical trial data and expert commentary regarding cardiovascular and renal side effects of atrasentan.analyze_data
15
The text explicitly alleges data tampering regarding Acute Kidney Injury (AKI) reporting in the SONAR study.expose_contradiction
16
The slide highlights discrepancies in reported clinical trial data, specifically regarding ESKD progression and adverse event reporting.analyze_data
17
The slide uses a table to highlight inconsistent reporting of Acute Kidney Injury (AKI) across different study groups and provides a narrative critique of cardiexpose_contradiction
18
The slide uses Kaplan-Meier survival curves to illustrate the effects of Atrasentan on primary composite renal outcomes in different patient cohorts.analyze_data
19
The slide argues that the drug causes fluid retention and anemia, contradicting the trial's stated conclusions.analyze_data
20
The text argues that the omission of hematocrit data in the SONAR trial masks a hemodynamic effect that would undermine claims of renal improvement.expose_contradiction
21
The slide uses a callout box for trial results and follows with a critical analysis of anemia as a side effect.expose_contradiction
22
Includes extensive footnotes citing regulatory documents and investor call transcripts.preempt_rebuttal
23
Includes a table detailing orphan drug designation and marketing approval for Filspari (sparsentan).preempt_rebuttal
24
This is a text-heavy research note page focusing on competitive critique and data skepticism.preempt_rebuttal
25
The slide critiques the visual representation of clinical trial data, specifically the 'time-distorting' nature of the x-axis in the provided graph.expose_contradiction
26
The slide highlights inconsistencies between SONAR study reports and FDA filings, suggesting data manipulation to favor the drug's safety profile.expose_contradiction
27
The slide uses a table of clinical trial results to illustrate a methodological critique of composite endpoints.expose_contradiction
28
The text focuses on statistical manipulation in clinical trial endpoints and discrepancies in patient count reporting between AFFINITY and ALIGN studies.expose_contradiction
29
The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.expose_contradiction
30
The slide uses a combination of text-based argument and visual data (charts) to expose potential manipulation of clinical trial reporting.expose_contradiction
31
Includes critical commentary on the ALIGN trial and potential data obfuscation.analyze_data
32
Figure from SONAR trial report.analyze_data
33
Poster format including background, baseline/safety data, efficacy results, and conclusions.summarize
34
Includes detailed diagrams of disease pathophysiology and clinical trial design.establish_context
35
The slide displays a forest plot comparing eGFR decline rates between atrasentan and placebo groups, segmented by pre-trial eGFR slope, UACR, and baseline eGFR.analyze_data